News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Carl Zeiss Meditec Inc. Announces New Developments and Innovations in Ophthalmology that Streamline Workflow and Enhance Patient Care


3/25/2011 9:34:25 AM

DUBLIN, Calif., March 25, 2011 /PRNewswire/ -- ASCRS Booth #2021 -- Carl Zeiss Meditec is presenting the newest additions to its Cataract, Refractive, Retina and Glaucoma Workplaces at The American Society of Cataract and Refractive Surgery's 2011 Symposium and Congress (ASCRS) at the San Diego Convention Center.

Enhanced Data Management Solution

FORUM® Ophthalmic Data Management System, which connects to ZEISS as well as other companies' ophthalmic DICOM compliant instruments, now supports HL7 interface for easy integration with many electronic medical record and electronic health record systems (EMRs and EHRs).

"The FORUM module has given us a great advantage in our practice in that we can see all the information provided by our EMR while simultaneously viewing images from our OCT, data from our visual field, or photos," said Dr. Jay McDonald of Fayetteville, AR. "The patient can be shown their test results right in the exam room, expediting their understanding of their conditions."

Latest Product Innovations

The IOLMaster® 500 is the fastest optical biometer available, and offers the best cataract penetration in the industry as well as proven keratometry. In addition, the IOLMaster 500 delivers highly precise measurements that are especially critical for meeting patient expectations for outcomes with premium IOLs.

The OPMI LUMERA® 700, a high performance microscope for cataract and retinal procedures is now available on a ceiling mount. The ceiling mount features a smooth lift function, ample headroom and remarkable reach, while optimizing space in the OR.

Recently FDA cleared and now available in the U.S. for retina treatment, the VISULAS Trion VITE is the world's first multi-wavelength laser that can apply multi-spot cascades for improved results and shorter treatment times. The VISULAS Trion VITE enables physicians to adjust their treatment strategy for specific patient needs.

The VisuMax® Femtosecond Laser delivers fast, precise and reproducible corneal incisions. With a repetition rate of 500 kHz, VisuMax offers best-in-class speed and treatment comfort in performing advanced femtosecond laser procedures. The VisuMax may now be used for keratoplasty applications in the U.S.

The MEL 80 Excimer Laser also offers highly precise laser vision correction for myopia. The hyperopia application is pending FDA approval and is not yet available for sale in the U.S.

"We are pleased to offer expanded, fully integrated solutions for our ophthalmic Workplaces that meet the demands of our customers," said Ludwin Monz, president and chief executive officer of Carl Zeiss Meditec AG. "We aim to provide our customers with the most advanced technologies that improve workflow, and enable physicians to deliver quality patient care."

ASCRS attendees are invited to visit Carl Zeiss Meditec's booth #2021 to see our latest innovations and participate in the following EyeWorld events being held in the San Diego Convention Center:

  • 21st Century Glaucoma Management: Practical Solutions You Can Use Today

Friday, March 25 (Rooms 1AB & 2)



5:00 - 6:30 p.m. Registration, Reception, and Clinical Case Presentations

  • What You Might be Missing: How the Comprehensive Ophthalmologist Can Gain Insight on Retinal Pathology with Cirrus HD-OCT

Saturday, March 26 (Room 9)



8:00 to 9:30 a.m. Registration, Breakfast, and Program

  • Innovations and Highlights in Refractive Surgery

Sunday, March 27 (Room 10)



5:30 to 6:00 pm Registration, Reception, and Program



Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology suppliers. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy. In the 2009/2010 (30 September) financial year, the around 2,200 employees generated revenue of EUR 676 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. Thirty-five percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and opto-electronics industry. Carl Zeiss offers innovative solutions for the future-oriented markets Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. In financial year 2009/2010, the Group generated revenue of around EUR 2.98 billion. From financial year 2010/2011 onwards, eyeglass lens manufacturer Carl Zeiss Vision shall be integrated as an autonomous business group (revenue of around EUR 880 million in financial year 2009/2010). The Carl Zeiss Group thus employs a workforce of around 24,000 worldwide, more than 10,000 of whom are based in Germany. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For further information see: http://www.meditec.zeiss.com/us

Contact:


Eva Sesselmann

Director Group Communications

Carl Zeiss Meditec AG

Goeschwitzer StraBe 51-52

07745 Jena

Telefon: +49 3641 220-331

Telefax: +49 3641 220-332

E-Mail: press@meditec.zeiss.com

Jackie Ferreira

Sr. Director, Marketing Communications

Carl Zeiss Meditec, Inc.

5160 Hacienda Dr.

Dublin, CA 94568

Phone : +1 925 557 4488

Fax: +1 925 557 4615

E-Mail: j.ferreira@meditec.zeiss.com




SOURCE Carl Zeiss Meditec, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES